PEP-Therapy
Innovative peptides
as targeted therapies for oncology
LATEST NEWS
March 17th, 2025
PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer.
September 26th, 2024
We are pleased to announce the publication of our translational study in BBA – Molecular Basis of Disease, showing that our lead product, PEP-010, induces apoptosis in cancer cells, which can be monitored by pharmacodynamic biomarkers.
+ READ MORE
+ READ MORE
September 3rd, 2024
We are thrilled to announce the publication of our work in Frontiers in Pharmacology, showing that our lead product, PEP-010, is effective in monotherapy and in combination with paclitaxel in resistant ovarian adenocarcinoma.
+ READ MORE
